• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Brainstorm Health: Eclipse Glasses, FDA Approves Pfizer Leukemia Drug, MS Drug Prices

By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Down Arrow Button Icon
August 18, 2017, 12:00 PM ET

Good morning and happy Friday, readers! This is Sy.

You’ve almost certainly heard about the total solar eclipse set to occur on Monday, August 21. The rare event will be visible in certain regions within more than a dozen states.

But, even with cosmic events, it’s important to put safety first. And when it comes to staring into the sun, that means protecting your eyes with special gear.

Unfortunately, some would-be viewers could have a bit of a problem with that. There have been reports of unauthorized eyewear that have led to recalls and suggestions from county officials in Richland, South Carolina (one of the areas where the eclipse will be visible in its totality) to seek “other options” than the free glasses made available if people feel uncomfortable. There have also been counterfeit pairs sold on Amazon (for which the company has offered refunds).

The American Astronomical Society (AAS) has an approved list of vendors for solar filters.

Read on for the day’s news, and enjoy your weekend!

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

DIGITAL HEALTH

IBM to team up with JDRF on type 1 diabetes. IBM and JDRF, an outfit focused on funding type 1 diabetes research, are teaming up to analyze the factors that may lead to that form of diabetes. The collaboration will involve creating machine learning methods which can analyze mountains of existing type 1 diabetes research in order to figure out risk factors and, hopefully, effective prevention measures.

INDICATIONS

FDA clears Pfizer drug for rare, fast-spreading cancer. The Food and Drug Administration (FDA) has approved Pfizer's Besponsa, a drug to treat a rare and vicious form of leukemia that can quickly kill patients. Besponsa is approved for adults with hard-to-treat or recurring forms of B-cell precursor acute lymphoblastic leukemia (ALL), which nearly 6,000 Americans are diagnosed with each year.(Fortune)

House Democrats push for explanation of high MS drug prices. House Democratic lawmakers have launched an investigation into pricing for multiple sclerosis drugs. Seven companies, including pharmaceutical giants like Biogen, Sanofi, Novartis, and Roche, have received letters from the House Government Oversight Committee requesting information on their pricing strategies.(Fortune)

REQUIRED READING

The Most Successful CEO of His Generation Steps Down, by Shawn Tully

If You Bought Google At Its IPO Price, Here's How Much Richer You'd Be, by Lucinda Shen

Among Startups, Microsoft and Google Are Giving AWS a Run for Its Money, by Barb Darrow

World Stocks Tumble As Market Hopes in Trump's Reform Agenda Fade, by Fortune Editors and Reuters

Produced by Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

Find past coverage. Sign up for other Fortunenewsletters.
About the Authors
By Clifton Leaf
See full bioRight Arrow Button Icon
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

Latest in Health

FDA
HealthDrugs
Female libido pill gets expanded approval for menopause by FDA
By Matthew Perrone and The Associated PressDecember 15, 2025
11 hours ago
HealthCommentary
Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping
By Max CunninghamDecember 14, 2025
2 days ago
Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
2 days ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
3 days ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
3 days ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
3 days ago

Most Popular

placeholder alt text
Success
'I had to take 60 meetings': Jeff Bezos says 'the hardest thing I've ever done' was raising the first million dollars of seed capital for Amazon
By Dave SmithDecember 15, 2025
16 hours ago
placeholder alt text
Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action, by blocking his calendar every afternoon from Wednesday to Friday 
By Preston ForeDecember 15, 2025
18 hours ago
placeholder alt text
Success
Sorry, six-figure earners: Elon Musk says that money will 'disappear' in the future as AI makes work (and salaries) irrelevant
By Orianna Rosa RoyleDecember 15, 2025
20 hours ago
placeholder alt text
AI
Deloitte's CTO on a stunning AI transformation stat: Companies are spending 93% on tech and only 7% on people
By Nick LichtenbergDecember 15, 2025
23 hours ago
placeholder alt text
Personal Finance
Current price of silver as of Monday, December 15, 2025
By Joseph HostetlerDecember 15, 2025
20 hours ago
placeholder alt text
North America
Ford writes down $19.5 billion as it pivots electric Lighting line of vehicles
By Sasha RogelbergDecember 15, 2025
12 hours ago

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.